Perception of Cure Among Patients With Metastatic Cancer

Hematopoietic and Lymphoid Cell Neoplasm Clinical Trial

Official title:

The Perception of Cure Among Patients With Metastatic Cancer

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04820894
• Other study ID #: 19322
• Secondary ID: NCI-2021-0181819
• Status: Withdrawn
• Start date: October 30, 2021
• Est. completion date: March 30, 2023

Study information

• Verified date: February 2022
• Source: City of Hope Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study collects information about perception of cure among patients with cancer that has spread to other places in the body (metastatic). This study aims to determine patients' perception (knowledge) before starting immunotherapy and if differences exist in understanding of treatment to stimulate or restore the ability of the body's immune (defense) system to fight infection and disease (immunotherapy) based on social and economic factors or on race/ethnicity.

Description:

PRIMARY OBJECTIVE:

I. To assess the proportion of patients with metastatic cancer who anticipate cure before starting immunotherapy.

SECONDARY OBJECTIVES:

I. To determine if expectations of cure are associated with quality of life and distress.

II. To determine if patients' perceptions differ by gender, age, and ethnicity.

OUTLINE:

Patients complete surveys over 30 minutes about sociodemographic information and perception of immunotherapy, over 10 minutes about expectations of cure, over 10 minutes about anxiety, over 10 minutes about depression, and over 30 minutes about physical well-being. Patients' medical records are reviewed.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: March 30, 2023
• Est. primary completion date: March 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Eligibility Criteria:

1. Patients must be aged 18 and over

2. Patients sufficiently fluent in English

3. Patients must have a cytologically or pathologically verified diagnosis of cancer

4. Patients must have measurable metastatic disease

5. Patients must be initiating immunotherapy

6. Patients must be undergoing evaluation and treatment at City of Hope Cancer Center

Related Conditions & MeSH terms

• Hematopoietic and Lymphoid Cell Neoplasm
• Metastatic Malignant Solid Neoplasm
• Neoplasm Metastasis
• Neoplasms

Intervention

Other:
• Electronic Medical Record
Medical records are reviewed
• Survey Administration
Complete surveys

Locations

Country	Name	City	State
United States	City of Hope Medical Center	Duarte	California

Sponsors (2)

Lead Sponsor	Collaborator
City of Hope Medical Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of patients	Will assess the percentage of patients who anticipate cure before starting immunotherapy, scoring a '1' on the Perception of cure tool, and anticipate >75% chance for a cure.	Up to 2 years
Primary	Patient Reported Outcomes Measurement Information System (PROMIS)	Descriptive analyses (e.g. frequency statistics) will be used to characterize the sample and to look at the association between Patient Reported Outcomes Measurement Information System (PROMIS) tool score with perception of cure score.	Up to 2 years
Primary	Functional Assessment of Cancer Therapy-General (FACT-G)	Descriptive analyses (e.g. frequency statistics) will be used to characterize the sample and to look at the association between Functional Assessment of Cancer Therapy-General (FACT-G) overall score with perception of cure score.	Up to 2 years
Primary	Perceptions of cure	Chi-square analyses will be used to examine perceptions of cure by sociodemographic characteristics: gender (male and female), age (< 60 and > 60), and ethnicity (white non-Hispanic, Hispanic, and other).	Up to 2 years